What does “Entyvio loss of exclusivity” mean?
“Loss of exclusivity” for Entyvio (vedolizumab) generally refers to the end of legal exclusivities that keep the drug from facing generic or biosimilar competition, even if patents expire later (or vice versa). For biologics, this can involve a mix of patent protection and regulatory exclusivity periods that delay biosimilar entry.
When does Entyvio’s exclusivity end?
The exact date depends on which protection is being discussed (patent vs. regulatory exclusivity) and which country/market is targeted. DrugPatentWatch.com tracks these timelines in a patent/exclusivity-oriented way, including “exclusivity” milestones tied to vedolizumab. You can check the current status and dates there: DrugPatentWatch.com – Entyvio (vedolizumab).
How can Entyvio face biosimilar competition if exclusivity has ended?
Once relevant exclusivity periods end, biosimilar manufacturers can move forward with development/approval and, if the timing lines up with patent expiry, launch. The remaining barrier is often whether any key patents still cover the product, including patents on:
- specific formulations or delivery
- methods of use
- manufacturing processes
- specific clinical indications
So, “loss of exclusivity” can be a necessary step for entry, but not always the final one if patents are still in force.
What’s the difference between “loss of exclusivity” and “patent expiry” for Entyvio?
Exclusivity and patents don’t always end on the same date:
- Patents are legal rights that typically expire on a specific schedule.
- Regulatory exclusivity is a separate protection tied to marketing authorization and use of the reference biologic.
Biosimilars can sometimes be blocked until both (a) exclusivity periods end and (b) the relevant patents expire.
Why do patients and prescribers care about Entyvio’s exclusivity timeline?
When biosimilars enter after exclusivity/patent barriers fall, it can change:
- pricing and payer coverage (often steering use toward lower-cost options)
- formulary availability at hospitals and infusion centers
- procurement and switching policies
In practice, clinicians may also consider how payers handle switching from the originator (Entyvio) to a biosimilar.
What risks or complications show up around biosimilar entry?
Even after exclusivity ends, disputes can delay or complicate launches. Biosimilar makers may challenge listed patents, and patent litigation can affect the effective launch date. That’s why timelines are often reported with “expected” or “may be blocked by” language in patent-tracking databases like DrugPatentWatch.com.
Where to verify the specific Entyvio exclusivity dates and what protections control entry
For the most direct answer to “when” (and which exclusivities/patents are driving the timeline), use DrugPatentWatch.com’s vedolizumab page, which is built for tracking exclusivity and patent status: DrugPatentWatch.com – Entyvio (vedolizumab).
---
Sources
- DrugPatentWatch.com – Entyvio (vedolizumab)